Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

249
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
249
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

322
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
322
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

315
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
315
Measurement of Blood Pressure01:17

Measurement of Blood Pressure

3.6K
Assessing blood pressure is a standard procedure executed in virtually all medical environments. The method utilized today was established over a hundred years ago by an innovative Russian doctor, Dr. Nikolai Korotkoff. The soft ticking noise, known as Korotkoff sounds, heard while taking blood pressure readings results from turbulent blood flow within the vessels. The apparatus required for this procedure includes a sphygmomanometer, a blood pressure cuff attached to a gauge, and a...
3.6K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

1.0K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

At any Level of Adiposity, Relatively Elevated Leptin Concentrations Are Associated With Decreased Insulin Sensitivity.

The Journal of clinical endocrinology and metabolism·2023
Same author

A randomized controlled trial investigating the effect of liraglutide on self-reported liking and neural responses to food stimuli in participants with obesity.

International journal of obesity (2005)·2023
Same author

Effectiveness of therapeutic patient education interventions for chronic diseases: A systematic review and meta-analyses of randomized controlled trials.

Frontiers in medicine·2023
Same author

Revue medicale suisse·2023
Same author

Effectiveness of Therapeutic Patient Education Interventions in Obesity and Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Nutrients·2022
Same author

Evolution of Therapeutic Patient Education: A Systematic Scoping Review and Scientometric Analysis.

International journal of environmental research and public health·2022

Related Experiment Video

Updated: Feb 26, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.4K

[Paradoxal decrease and metabolic effects of BNP in obese patient].

Rémy C Martin-Du-Pan1, Alain Golay2

  • 1Spécialiste FMH-Médecine interne-endocrinologie, 47 chemin Sur-Rang, 1234 Vessy.

Revue Medicale Suisse
|July 20, 2017
PubMed
Summary
This summary is machine-generated.

Natriuretic peptides (NP), like BNP, are crucial for heart health. In obesity, normal BNP levels may not rule out heart failure (HF), requiring adjustments for obesity and HF stage.

More Related Videos

A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats
06:28

A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats

Published on: April 28, 2023

1.4K
En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries
08:58

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries

Published on: February 25, 2016

10.1K

Related Experiment Videos

Last Updated: Feb 26, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.4K
A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats
06:28

A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats

Published on: April 28, 2023

1.4K
En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries
08:58

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries

Published on: February 25, 2016

10.1K

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Disorders

Background:

  • Natriuretic peptides (NP), including atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), are synthesized by cardiomyocytes in response to cardiac wall stress.
  • These peptides possess vasodilatory and natriuretic properties, counteracting volume and pressure overload characteristic of heart failure (HF).
  • Reduced NP levels are noted in individuals with obesity, diabetes, and insulin resistance, potentially contributing to associated hypertension and obesity itself due to impaired lipolysis.

Purpose of the Study:

  • To investigate the implications of natriuretic peptide levels in the context of obesity and heart failure.
  • To determine if standard BNP levels are adequate for diagnosing heart failure in obese individuals.
  • To highlight the need for obesity-adjusted reference ranges for NP in clinical practice.

Main Methods:

  • Review of existing literature on natriuretic peptides, obesity, diabetes, insulin resistance, and heart failure.
  • Analysis of the physiological roles of NP, including their effects on vasodilation, natriuresis, and lipolysis.
  • Evaluation of clinical observations regarding NP levels in different patient populations.

Main Results:

  • Decreased NP levels are frequently observed in obese, diabetic, and insulin-resistant individuals.
  • Low NP levels may contribute to the development and exacerbation of hypertension and obesity.
  • Standard BNP values may be insufficient to exclude heart failure in obese patients.

Conclusions:

  • Obesity can influence natriuretic peptide levels, complicating their interpretation in heart failure diagnosis.
  • Normal BNP levels in obese individuals do not preclude the presence of heart failure.
  • BNP reference ranges require adjustment based on the degree of obesity and the stage of heart failure for accurate clinical assessment.